|Table of Contents|

mRNA tumor vaccines:Research progress and clinical application prospects

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 09
Page:
1740-1748
Research Field:
Publishing date:

Info

Title:
mRNA tumor vaccines:Research progress and clinical application prospects
Author(s):
JIANG Junshan1; 2; LI Limao1; 2; CAI Huazhong2
1.School of Medicine，Jiangsu University,Jiangsu Zhenjiang 212000,China；2.Affiliated Hospital of Jiangsu University,Jiangsu Zhenjiang 212000,China.
Keywords:
mRNA vaccine; personalized tumor vaccine; neoantigen
PACS:
R730.3
DOI:
10.3969/j.issn.1672-4992.2024.09.029
Abstract:
Immunotherapy provides a good adjuvant effect for tumor treatment.And messenger RNA(mRNA) tumor vaccine has an available tumor immune activation effect,which provides a potential application prospect for tumor adjuvant therapy.mRNA vaccines can activate or enhance the ability of the human immune system to specifically recognize antigens and ultimately result in anti-tumor effects.Compared with other vaccine platforms,mRNA tumor vaccines have the characteristics of safety,non-integration,and loading with multiple antigens.The different mutation types of tumors lead to certain individual differences in tumor treatment,and the choice of tumor antigen is particularly important.At the same time,mRNA modification also enhance the stability and translation efficiency of mRNA.All these affect the anti-tumor effect of mRNA vaccines.Many personalized mRNA tumor vaccines have shown good safety and immunogenicity in clinical trials.Therefore,through this review,we can better understand the role of mRNA tumor vaccines and the clinical value of personalized tumor vaccines.What's more,mRNA vaccine provide more effective treatment options for tumor adjuvant therapy combined with existing treatment methods.

References:

［1］BLUESTONE JA,MACKAY CR,O'SHEA JJ,et al.The functional plasticity of T cell subsets［J］.Nat Rev Immunol,2009,9(11):811-816.
［2］COUSSENS LM,ZITVOGEL L,PALUCKA AK.Neutralizing tumor-promoting chronic inflammation:A magic bullet［J］.Science,2013,339(6117):286-291.
［3］SAXENA M,VAN DER BURG SH,MELIEF CJM,et al.Therapeutic cancer vaccines［J］.Nat Rev Cancer,2021,21(6):360-378.
［4］CHEEVER MA,HIGANO CS.PROVENGE(Sipuleucel-T) in prostate cancer:The first FDA-approved therapeutic cancer vaccine［J］.Clin Cancer Res,2011,17(11):3520-3526.
［5］FU C,MA T,ZHOU L,et al.Dendritic cell-based vaccines against cancer:Challenges,advances and future opportunities［J］.Immunol Invest,2022,51(8):2133-2158.
［6］FRANKENBERGER B,REGN S,GEIGER C,et al.Cell-based vaccines for renal cell carcinoma:Genetically-engineered tumor cells and monocyte-derived dendritic cells［J］.World J Urol,2005,23(3):166-174.
［7］MALONIS RJ,LAI JR,VERGNOLLE O.Peptide-based vaccines:Current progress and future challenges［J］.Chem Rev,2020,120(6):3210-3229.
［8］ROY DG,GEOFFROY K,MARGUERIE M,et al.Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination［J］.Nat Commun,2021,12(1):2626.
［9］MIAO L,ZHANG Y,HUANG L.mRNA vaccine for cancer immunotherapy［J］.Mol Cancer,2021,20(1):41.
［10］GUO C,MANJILI MH,SUBJECK JR,et al.Therapeutic cancer vaccines:Past,present,and future［J］.Adv Cancer Res,2013,119:421-475.
［11］RODEN RBS,STERN PL.Opportunities and challenges for human papillomavirus vaccination in cancer［J］.Nat Rev Cancer,2018,18(4):240-254.
［12］WOLFF JA,MALONE RW,WILLIAMS P,et al.Direct gene transfer into mouse muscle in vivo［J］.Science,1990,247(4949 Pt 1):1465-1468.
［13］CONRY RM,LOBUGLIO AF,WRIGHT M,et al.Characterization of a messenger RNA polynucleotide vaccine vector［J］.Cancer Res,1995,55(7):1397-1400.
［14］KARIKO K,MURAMATSU H,WELSH FA,et al.Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability［J］.Mol Ther,2008,16(11):1833-1840.
［15］PERSANO S,GUEVARA ML,LI Z,et al.Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination［J］.Biomaterials,2017,125:81-89.
［16］RITTIG SM,HAENTSCHEL M,WEIMER KJ,et al.Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients［J］.Molecular Therapy,2011,19(5):990-999.
［17］SAHIN U,DERHOVANESSIAN E,MILLER M,et al.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer［J］.Nature,2017,547(7662):222-226.
［18］KWON S,KWON M,IM S,et al.mRNA vaccines:The most recent clinical applications of synthetic mRNA［J］.Arch Pharm Res,2022,45(4):245-262.
［19］VAN TENDELOO VF,PONSAERTS P,BERNEMAN ZN.mRNA-based gene transfer as a tool for gene and cell therapy［J］.Curr Opin Mol Ther,2007,9(5):423-431.
［20］LINARES-FERNANDEZ S,LACROIX C,EXPOSITO JY,et al.Tailoring mRNA vaccine to balance innate/adaptive immune response［J］.Trends Mol Med,2020,26(3):311-323.
［21］SCHUSTER SC.Next-generation sequencing transforms today's biology［J］.Nat Methods,2008,5(1):16-18.
［22］LIU Y,MIYOSHI H,NAKAMURA M.Nanomedicine for drug delivery and imaging:A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles［J］.Int J Cancer,2007,120(12):2527-2537.
［23］TURAJLIC S,LITCHFIELD K,XU H,et al.Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype:A pan-cancer analysis［J］.Lancet Oncol,2017,18(8):1009-1021.
［24］YANG W,LEE KW,SRIVASTAVA RM,et al.Immunogenic neoantigens derived from gene fusions stimulate T cell responses［J］.Nat Med,2019,25(5):767-775.
［25］CASTLE JC,KREITER S,DIEKMANN J,et al.Exploiting the mutanome for tumor vaccination［J］.Cancer Res,2012,72(5):1081-1091.
［26］DOLLED-FILHART MP,LEE M,OUYANG CW,et al.Computational and bioinformatics frameworks for next-generation whole exome and genome sequencing［J］.Scientific World Journal,2013,2013,730210.
［27］CREECH AL,TING YS,GOULDING SP,et al.The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction［J］.Proteomics,2018,18(12):e1700259.
［28］RICHARD G,PRINCIOTTA MF,BRIDON D,et al.Neoantigen-based personalized cancer vaccines:The emergence of precision cancer immunotherapy［J］.Expert Rev Vaccines,2022,21(2):173-184.
［29］BENTLEY DR,BALASUBRAMANIAN S,SWERDLOW HP,et al.Accurate whole human genome sequencing using reversible terminator chemistry［J］.Nature,2008,456(7218):53-59.
［30］REUTER JA,SPACEK DV,SNYDER MP.High-throughput sequencing technologies［J］.Mol Cell,2015,58(4):586-597.
［31］LEVY SE,BOONE BE.Next-generation sequencing strategies［J］.Cold Spring Harb Perspect Med,2019,9(7):a025791.
［32］BOCCALETTO P,MACHNICKA MA,PURTA E,et al.MODOMICS:A database of RNA modification pathways.2017 update［J］.Nucleic Acids Res,2018,46(D1):D303-D307.
［33］WANG X,LU Z,GOMEZ A,et al.N6-methyladenosine-dependent regulation of messenger RNA stability［J］.Nature,2014,505(7481):117-120.
［34］WANG X,ZHAO BS,ROUNDTREE IA,et al.N(6)-methyladenosine modulates messenger RNA translation efficiency［J］.Cell,2015,161(6):1388-1399.
［35］BOHNSACK K,HOBARTNER C,BOHNSACK M.Eukaryotic 5-methylcytosine(m5C) RNA methyltransferases:Mechanisms,cellular functions,and links to disease［J］.Genes,2019,10(2):102.
［36］ANDERSON BR,MURAMATSU H,NALLAGATLA SR,et al.Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation［J］.Nucleic Acids Res,2010,38(17):5884-5892.
［37］KORE AR,SHANMUGASUNDARAM M,CHARLES I,et al.Locked nucleic acid(LNA)-modified dinucleotide mRNA cap analogue:Synthesis,enzymatic incorporation,and utilization［J］.J Am Chem Soc,2009,131(18):6364-6375.
［38］NICHOLSON AL,PASQUINELLI AE.Tales of detailed poly(A) tails［J］.Trends Cell Biol,2019,29(3):191-200.
［39］COBB M.Who discovered messenger RNA［J］.Curr Biol,2015,25(13):R526-532.
［40］INGELS J,DE COCK L,MAYER RL,et al.Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials［J］.Cytotherapy,2022,24(2):213-222.
［41］CHAMBERLIN M,RING J.Characterization of T7-specific ribonucleic acid polymerase 1.General properties of the enzymatic reaction and the template specificity of the enzyme［J］.J Biol Chem,1973,248(6):2235-2244.
［42］ENSINGER MJ,MARTIN SA,PAOLETTI E,et al.Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus［J］.Proc Natl Acad Sci USA,1975,72(7):2525-2529.
［43］HENDERSON JM,UJITA A,HILL E,et al.Cap 1 messenger RNA synthesis with co-transcriptional cleanCap［(R)］analog by in vitro transcription［J］.Curr Protoc,2021,1(2):e39.
［44］ALEMANY R.Viruses in cancer treatment［J］.Clin Transl Oncol,2013,15(3):182-188.
［45］WANG Y,WANG Y,KANG N,et al.Construction and immunological evaluation of CpG-Au@HBc virus-like nanoparticles as a potential vaccine［J］.Nanoscale Res Lett,2016,11(1):338.
［46］BERILLO D,YESKENDIR A,ZHARKINBEKOV Z,et al.Peptide-based drug delivery systems［J］.Medicina,2021,57(11):1209.
［47］LIU MA,ZHOU T,SHEETS RL,et al.WHO informal consultation on regulatory considerations for evaluation of the quality,safety and efficacy of RNA-based prophylactic vaccines for infectious diseases,20-22 April 2021［J］.Emerg Microbes Infect,2022,11(1):384-391.
［48］DING Z,LI Q,ZHANG R,et al.Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer［J］.Signal Transduct Target Ther,2021,6(1):26.
［49］CHEN Z,ZHANG S,HAN N,et al.A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment［J］.Front Immunol,2021,12:691605.
［50］LI J,HUI AM,ZHANG X,et al.Immune persistence and safety after SARS-CoV-2 BNT162b1 mRNA vaccination in Chinese adults:A randomized,placebo-controlled,double-blind phase 1 trial［J］.Adv Ther,2022,39(8):3789-3798.
［51］LI J,HUI A,ZHANG X,et al.Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults:A randomized,placebo-controlled,double-blind phase 1 study［J］.Nat Med,2021,27(6):1062-1070.
［52］PAPACHRISTOFILOU A,HIPP MM,KLINKHARDT U,et al.Phase Ⅰb evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy,BI1361849(CV9202),combined with local radiation treatment in patients with stage Ⅳ non-small cell lung cancer［J］.J Immunother Cancer,2019,7(1):38.
［53］CARRENO BM,MAGRINI V,BECKER-HAPAK M,et al.Cancer immunotherapy.A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells［J］.Science,2015,348(6236):803-808.
［54］CAI Z,SU X,QIU L,et al.Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion［J］.Mol Cancer,2021,20(1):164.
［55］CAFRI G,GARTNER JJ,ZAKS T,et al.mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer［J］.J Clin Invest,2020,130(11):5976-5988.
［56］ROJAS LA,SETHNA Z,SOARES KC,et al.Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer［J］.Nature,2023,618(7963):144-150.

Memo

Memo:
江苏省镇江市科技计划（市重点研发计划-社会发展）项目（编号：SH2022042）
Last Update: 2024-03-29